EDIT vs PLTR · rev $32.3M vs P/E 584, rev $4.48B
Editas Medicine Inc (EDIT) versus Palantir Technologies Inc. Class A Common Stock (PLTR) — a side-by-side from cached financials, not a winner call.
Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ.
Palantir Technologies Inc. Class A Common Stock (PLTR) is a software - infrastructure company listed on US. It is led by Alex Karp.
Latest reported EDIT revenue for 2024-12-31 was $32.3M. Net income was -$237.1M. Revenue was down 58.6% from 2023-12-31 to 2024-12-31. EDIT currently screens at market cap $375.2M.
Latest reported PLTR revenue for 2025-12-31 was $4.48B. Net income was $1.63B. Revenue was up 56.2% from 2024-12-31 to 2025-12-31. PLTR currently screens at market cap $317.08B and trailing P/E 584.2.
EDIT currently screens at market cap $375.2M. PLTR currently screens at market cap $317.08B and trailing P/E 584.2.
Not investment advice. Open the EDIT and PLTR stock pages for the full models.
Not investment advice.